Funding of $50M was raised by NuProbe Global, a Houston-based molecular diagnostics and genomics company.
Panlin Capital, CR-CP Life Science Fund and AstraZeneca CICC Fund co-led the round. The round also included existing investors Sequoia Capital China and Biotrack Capital as well as new investors Pappas Capital and Haoreng Capital.
The funds will be used in expanding commercial operations, accelerating IVD product clinical research and regulatory submissions, as well as to develop new genomics- and molecular diagnosis technologies.
Led by Yingshuang Chai, CEO, and David Zhang, Co-Founder of NuProbe Global and CEO of NuProbe USA, NuProbe Global is a genomics and molecular diagnostics company with molecular diagnostic technologies to improve the sensitivity of sequencing mutations and copy number variations by over 10-fold. It has locations in Houston, USA, Shanghai China, and Suzhou China.
The company has been involved in several research collaborations since the last round of funding in 2021. It also has clinical collaborations and collaborations with more than 400 hospitals.